Ensuring accurate RNA detection within specific cellular contexts is essential for advancing translational research and clinical applications. However, the lack of robust validation of probes targeting newly discovered RNA molecules remains a key bottleneck for clinical translation. Accurate identification of RNA within specific cells, particularly in cytoplasmic regions, presents a significant challenge due to difficulties in determining cell boundaries and ensuring probe specificity.

In this webinar, Molecular Instruments will address these challenges by introducing Dual Channel™ Validation, a novel approach that assesses both the specificity and sensitivity of HCR™ Pro RNA-ISH. This comprehensive evaluation facilitates the translation of high-value RNA-ISH assays from research to clinical settings, ultimately enabling reliable RNA quantification. Additionally, experts from Visiopharm will discuss the integration of their Discovery software, a powerful deep-learning solution powered by AI that enhances the cell segmentation and RNA spot localization, leading to improved RNA quantification especially within the tumor microenvironment.

We will discuss how the combination of protease-free RNA-ISH, co-detection with protein markers, and AI-powered cell boundary recognition unlocks new possibilities for high-fidelity RNA visualization in clinical research. Join us to explore how this end-to-end assay validation strategy can improve the accuracy and clinical relevance of RNA-ISH analyses.

Key Learning Objectives:

• Understand the limitations of traditional RNA staining techniques and how MI’s Dual Channel™ Validation enhances specificity and sensitivity in RNA-ISH assays.
• Learn how AI-driven cell boundary detection using Visiopharm’s Discovery software improves RNA localization and quantification accuracy.
• Explore the power of integrating HCR™ Pro RNA-ISH with Discovery, enabling high-precision RNA quantification within complex tissue environments.

Regan Baird, SVP Research Commercial Strategy Deployment at Visiopharm

Regan Baird, PhD received his degree from Temple University in Philadelphia, Pa. in Biochemistry and Postdoctoral Fellowship at the Beth Israel Deaconess Medical Center in Boston, Ma. Dr. Baird has spent the past 2 decades in cellular and tissue imaging and analysis. Dr. Baird is currently Visiopharm’s SVP of Research Commercial Strategy Deployment. Talk to him about the practical aspects of AI, Machine Learning, Deep Learning, Tissue Multiplex, and Clinical Integration.

Dan Winkowski, SVP Research Commercial Strategy Deployment at Visiopharm

Dan is a senior technical specialist in image analysis, supporting the US sales team for Visiopharm. He was trained as a neuroscientist and has spent over a decade in academia, specializing in advanced imaging methods and designing automated digital image analysis workflows.

Randy Chen, Director of R&D at Molecular Instruments

Randy is the Director of R&D at Molecular Instruments. He joined MI as a scientist and led the development of HCR™ Pro RNA-ISH protocols for major automated platforms, including the DISCOVERY ULTRA, BOND RX, and ONCORE Pro X. His work has enabled seamless integration of HCR™ assays into biopharma and academic workflows. Currently, Randy is focused on advancing next-generation HCR™ products and expanding the technology’s applications into the clinical space.